Skip to main content
ROIV
NASDAQ Life Sciences

Roivant Sciences Boosts Share Buyback Program to $1 Billion

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$28.5
Mkt Cap
$19.932B
52W Low
$8.73
52W High
$29.2
52W Position info
226% above low
Off High info
2.4% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ROIV has more than doubled off its 52-week low of $8.73.

Summary

Roivant Sciences has increased its share repurchase authorization by $500 million, bringing the total program to $1 billion. This expansion of the buyback program, initially mentioned in the company's February 6th 10-Q filing, represents a material capital allocation decision. The $1 billion authorization signals strong management confidence and a commitment to returning capital to shareholders, especially as the stock trades near its 52-week high. This move follows recent positive news regarding the FDA's Priority Review acceptance for brepocitinib, suggesting a strategic use of capital to enhance shareholder value and potentially support the stock price. Traders will likely view this as a positive development, indicating financial strength and a proactive approach to capital management.

At the time of this announcement, ROIV was trading at $28.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.9B. The 52-week trading range was $8.73 to $29.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

ROIV - Latest Insights

ROIV
Nov 09, 2026, 7:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.37
Real-time Price: $39.53 info
Change: -$1.84 (-4%) info
Market Cap: $28.642B info
ROIV
Nov 09, 2026, 7:17 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $41.00
Real-time Price: $39.53 info
Change: -$1.47 (-4%) info
Market Cap: $28.642B info
ROIV
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $40.39
Real-time Price: $39.53 info
Change: -$0.860 (-2%) info
Market Cap: $28.642B info
ROIV
Oct 21, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.20
Real-time Price: $39.53 info
Change: +$3.33 (+9%) info
Market Cap: $28.642B info
ROIV
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $36.60
Real-time Price: $39.53 info
Change: +$2.93 (+8%) info
Market Cap: $28.642B info